Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 2Thoracic 2

Conditions

Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × demcizumab × Gastrointestinal × Clear all
NCT02289898 2020-09-28

YOSEMITE

Mereo BioPharma

Phase 2 Completed
207 enrolled 12 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01189929 2020-09-09

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Mereo BioPharma

Phase 1 Completed
57 enrolled
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT01189942 2020-09-09

A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer

Mereo BioPharma

Phase 1 Completed
18 enrolled
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡